News

Seres Therapeutics, Inc. announced that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has awarded the company up to $3.6 million in additional…
Read More...

The U.S. Food and Drug Administration (FDA) has unveiled a new draft guidance aimed at making the development of biosimilar medicines—lower-cost alternatives to expensive biologic…
Read More...

Alexion, AstraZeneca Rare Disease, announced that the European Commission has approved Koselugo (selumetinib) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN)…
Read More...

Kazia Therapeutics Limited announced plans to hold a follow-up Type C meeting with the U.S. Food and Drug Administration (FDA) to discuss new overall survival (OS) findings from…
Read More...

Novartis announced that it has successfully completed the acquisition of Tourmaline Bio, Inc., making the biotechnology company an indirect wholly owned subsidiary of Novartis.…
Read More...

Guardant Health, a leader in precision oncology, has announced a strategic partnership with Zephyr AI, a precision medicine company specializing in artificial intelligence, to…
Read More...

Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has expanded the approval of WINREVAIR™ (sotatercept-csrk) for the…
Read More...

Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic treatments for rare bleeding and thrombotic disorders, has raised $157 million in a heavily…
Read More...

Lifecore Biomedical, Inc. and PolyPeptide Laboratories, Inc. have announced a collaboration to offer fully integrated development and manufacturing services for peptide-based…
Read More...

GSK plc has entered into an agreement with Syndivia, a private biotechnology company specializing in next-generation antibody-drug conjugates (ADCs), granting GSK exclusive worldwide…
Read More...

Eli Lilly and Company announced it will acquire Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage biotechnology company pioneering intravitreal gene therapies for eye…
Read More...

Alkermes plc has announced plans to acquire Avadel Pharmaceuticals plc in a $2.1 billion all-cash deal, marking a major strategic move to expand its presence into the fast-growing sleep…
Read More...

Ipsen has announced plans to acquire ImCheck Therapeutics, a private French biotechnology company developing next-generation immuno-oncology treatments, in a deal that expands Ipsen’s…
Read More...

GSK plc announced today that the US Food and Drug Administration (FDA) has approved its cancer therapy Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and…
Read More...

Takeda Pharmaceutical Company has entered a license and collaboration agreement with Innovent Biologics to develop, manufacture and commercialize two late-stage oncology medicines —…
Read More...

Ventus Therapeutics, a clinical-stage biopharmaceutical company, has announced a multi-year collaboration with Genentech, part of the Roche Group, to discover and optimize novel…
Read More...

Roche announced positive results from the Phase III IMvigor011 study evaluating Tecentriq® (atezolizumab) as an adjuvant treatment for muscle-invasive bladder cancer (MIBC) in patients…
Read More...

GSK plc announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of a new prefilled…
Read More...

Glaukos Corporation announced that the U.S. Food and Drug Administration (FDA) has approved its novel corneal cross-linking therapy, Epioxa™ (Epioxa™ HD / Epioxa™), marking a major…
Read More...

Roche has announced positive phase III results from its IMvigor011 study, showing that Tecentriq® (atezolizumab) significantly improves survival outcomes in patients with…
Read More...